Document is current
Any future updates will be listed below
-
Authors
Vetter, Valentin Max https://orcid.org/0000-0001-5003-7766
Junge, Marit Philine https://orcid.org/0009-0001-0333-3105
Drevon, Christian A.
Gundersen, Thomas E.
Homann, Jan
Lill, Christina M. https://orcid.org/0000-0002-2805-1307
Lindenberger, Ulman
Pawelec, Graham
Bertram, Lars https://orcid.org/0000-0002-0108-124X
Gerstorf, Denis
Demuth, Ilja https://orcid.org/0000-0002-4340-2523
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 9 December 2025
Accepted: 19 February 2026
First Online: 6 March 2026
Declarations
:
: All participants gave written informed consent. The Ethics Committee of the Charité – Universitätsmedizin Berlin approved the study (approval numbers EA2/029/09 and EA2/144/16). The study was conducted in accordance with the Declaration of Helsinki and was registered in the German Clinical Trials Registry as DRKS00009277 (BASE-II) and DRKS00016157 (GendAge).
: Not applicable.
: CAD is cofounder, stockowner, board member and consultant in Vitas Ltd. TEG is CEO and stockowner in Vitas Ltd.
